Transferrin is an important serum protein that mediates iron transport into cells via the transferrin receptor, a function that is essential for cell growth and metabolism. PerkinElmer’s Transferrin-Vivo 750 fluorescent probe is a NIR-labeled in vivo imaging agent that detects transferrin receptor levels associated with an altered metabolic need for iron in cancer and inflammatory cells. Transferrin-Vivo 750 fluorescent agent can also detect normal transferrin receptor levels in the liver as well as decreased expression due to altered iron metabolism associated with drug-induced liver injury.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
|Fluorescent Agent Type||Targeted|
|Product Brand Name||Transferrin-Vivo|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.